GlassScriptPhysician profile
David Finkelman
NPI 1063485332
$3,455.83
in general payments reported to CMS, 2019-2025
26 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $263 · 2021: $425 · 2022: $785 · 2023: $590 · 2024: $579 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Education: $18.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.29 |
| Education | $18.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.98 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $447.44 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $426.20 | 2022-2025 | |
| Janssen Biotech, INC. | $221.75 | 2019-2024 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $149.44 | 2019-2023 | Dificid |
| Celgene Corporation | $140.22 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $95.59 | 2019-2024 | |
| Pfizer INC. | $87.98 | 2019-2025 | |
| Qol Medical, LLC | $87.70 | 2023-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $75.38 | 2022-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $66.52 | 2023-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $52.69 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $47.94 | 2022-2023 | |
| Ardelyx, INC. | $44.03 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $38.09 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.93 | 2019-2020 | |
| Boston Scientific Corporation | $34.79 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $31.96 | 2022 | |
| Lilly USA, LLC | $26.04 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $25.40 | 2023 | Rebyota |
| Gilead Sciences, INC. | $18.85 | 2019 | |
| Celltrion USA INC. | $18.46 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $18.00 | 2025 | Rezdiffra |
| Intra-Sana Laboratories | $16.30 | 2021 | |
| Ucb, INC. | $13.72 | 2020 | |
| Braintree Laboratories, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Finkelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.